Correlation Between Inhibikase Therapeutics and Pfizer
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Pfizer at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Pfizer into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and Pfizer Inc, you can compare the effects of market volatilities on Inhibikase Therapeutics and Pfizer and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Pfizer. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Pfizer.
Diversification Opportunities for Inhibikase Therapeutics and Pfizer
-0.16 | Correlation Coefficient |
Good diversification
The 3 months correlation between Inhibikase and Pfizer is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Pfizer Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pfizer Inc and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Pfizer. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pfizer Inc has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Pfizer go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and Pfizer
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 4.5 times more return on investment than Pfizer. However, Inhibikase Therapeutics is 4.5 times more volatile than Pfizer Inc. It trades about 0.01 of its potential returns per unit of risk. Pfizer Inc is currently generating about 0.01 per unit of risk. If you would invest 272.00 in Inhibikase Therapeutics on November 3, 2024 and sell it today you would lose (80.00) from holding Inhibikase Therapeutics or give up 29.41% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 99.6% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. Pfizer Inc
Performance |
| Timeline |
| Inhibikase Therapeutics |
| Pfizer Inc |
Inhibikase Therapeutics and Pfizer Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and Pfizer
The main advantage of trading using opposite Inhibikase Therapeutics and Pfizer positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Pfizer can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will offset losses from the drop in Pfizer's long position.| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
| Pfizer vs. Agilent Technologies | Pfizer vs. Equillium | Pfizer vs. 23Andme Holding Co | Pfizer vs. DiaMedica Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Complementary Tools
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |